Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms

B. G. DeRubertis, B. M. Stiles, A. Bhargava, N. J. Gusani, M. Hezel, M. D'Angelica, Y. Fong

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In this model of hepatic micrometastases, the antitumor efficacy and role of the T-cell and natural killer (NK) cell populations were studied for oncolytic herpes simplex virus type-1 (HSV-1) viral mutants containing the granulocyte-monocyte colony stimulating factor (GM-CSF (NV1034)) or interluken-12 (IL-12 (NV1042)) cytokine genes. These were compared to saline and control virus (NV1023) in vitro and in vivo. HSV-1 mutants were assessed for cytotoxicity, replication and cytokine expression in CT-26 cells. A syngeneic micrometastatic liver model was then established in naive and immune cell-depleted animals to assess the antitumor efficacy of these viruses. In vitro cytotoxicity and viral replication were similar for each virus, resulting in greater than 80 and 98% cytotoxicity at multiplicity of infection of 1 and 10, respectively. Peak viral titers were 25- to 50-fold higher than initial titer and were not significantly different between viruses. In vivo, all three viruses reduced metastases relative to control, but cytokine-secreting viruses did so with greater efficacy compared to NV1023. This effect was abrogated by T-cell depletion, but not NK-cell depletion. Single-agent therapy with oncolytic viral agents containing GM-CSF or IL-12 is effective in a murine model of liver metastases and likely involves direct viral oncolysis and actions of specific immune effector cells.

Original languageEnglish (US)
Pages (from-to)590-597
Number of pages8
JournalCancer Gene Therapy
Volume14
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Cytokines
Viruses
T-Lymphocytes
Liver
Neoplasms
Human Herpesvirus 1
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Natural Killer Cells
Oncolytic Viruses
Neoplasm Metastasis
Neoplasm Micrometastasis
Granulocyte Colony-Stimulating Factor
Monocytes
Infection
Population
Genes
In Vitro Techniques
Therapeutics

Keywords

  • Cytokine gene therapy
  • HSV
  • Liver cancer
  • Metastases
  • Murine model
  • Oncolytic viral therapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. / DeRubertis, B. G.; Stiles, B. M.; Bhargava, A.; Gusani, N. J.; Hezel, M.; D'Angelica, M.; Fong, Y.

In: Cancer Gene Therapy, Vol. 14, No. 6, 06.2007, p. 590-597.

Research output: Contribution to journalArticle

DeRubertis, B. G. ; Stiles, B. M. ; Bhargava, A. ; Gusani, N. J. ; Hezel, M. ; D'Angelica, M. ; Fong, Y. / Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. In: Cancer Gene Therapy. 2007 ; Vol. 14, No. 6. pp. 590-597.
@article{de7f8bb94de4420ba38a05edfe9628dc,
title = "Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms",
abstract = "In this model of hepatic micrometastases, the antitumor efficacy and role of the T-cell and natural killer (NK) cell populations were studied for oncolytic herpes simplex virus type-1 (HSV-1) viral mutants containing the granulocyte-monocyte colony stimulating factor (GM-CSF (NV1034)) or interluken-12 (IL-12 (NV1042)) cytokine genes. These were compared to saline and control virus (NV1023) in vitro and in vivo. HSV-1 mutants were assessed for cytotoxicity, replication and cytokine expression in CT-26 cells. A syngeneic micrometastatic liver model was then established in naive and immune cell-depleted animals to assess the antitumor efficacy of these viruses. In vitro cytotoxicity and viral replication were similar for each virus, resulting in greater than 80 and 98{\%} cytotoxicity at multiplicity of infection of 1 and 10, respectively. Peak viral titers were 25- to 50-fold higher than initial titer and were not significantly different between viruses. In vivo, all three viruses reduced metastases relative to control, but cytokine-secreting viruses did so with greater efficacy compared to NV1023. This effect was abrogated by T-cell depletion, but not NK-cell depletion. Single-agent therapy with oncolytic viral agents containing GM-CSF or IL-12 is effective in a murine model of liver metastases and likely involves direct viral oncolysis and actions of specific immune effector cells.",
keywords = "Cytokine gene therapy, HSV, Liver cancer, Metastases, Murine model, Oncolytic viral therapy",
author = "DeRubertis, {B. G.} and Stiles, {B. M.} and A. Bhargava and Gusani, {N. J.} and M. Hezel and M. D'Angelica and Y. Fong",
year = "2007",
month = "6",
doi = "10.1038/sj.cgt.7701053",
language = "English (US)",
volume = "14",
pages = "590--597",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms

AU - DeRubertis, B. G.

AU - Stiles, B. M.

AU - Bhargava, A.

AU - Gusani, N. J.

AU - Hezel, M.

AU - D'Angelica, M.

AU - Fong, Y.

PY - 2007/6

Y1 - 2007/6

N2 - In this model of hepatic micrometastases, the antitumor efficacy and role of the T-cell and natural killer (NK) cell populations were studied for oncolytic herpes simplex virus type-1 (HSV-1) viral mutants containing the granulocyte-monocyte colony stimulating factor (GM-CSF (NV1034)) or interluken-12 (IL-12 (NV1042)) cytokine genes. These were compared to saline and control virus (NV1023) in vitro and in vivo. HSV-1 mutants were assessed for cytotoxicity, replication and cytokine expression in CT-26 cells. A syngeneic micrometastatic liver model was then established in naive and immune cell-depleted animals to assess the antitumor efficacy of these viruses. In vitro cytotoxicity and viral replication were similar for each virus, resulting in greater than 80 and 98% cytotoxicity at multiplicity of infection of 1 and 10, respectively. Peak viral titers were 25- to 50-fold higher than initial titer and were not significantly different between viruses. In vivo, all three viruses reduced metastases relative to control, but cytokine-secreting viruses did so with greater efficacy compared to NV1023. This effect was abrogated by T-cell depletion, but not NK-cell depletion. Single-agent therapy with oncolytic viral agents containing GM-CSF or IL-12 is effective in a murine model of liver metastases and likely involves direct viral oncolysis and actions of specific immune effector cells.

AB - In this model of hepatic micrometastases, the antitumor efficacy and role of the T-cell and natural killer (NK) cell populations were studied for oncolytic herpes simplex virus type-1 (HSV-1) viral mutants containing the granulocyte-monocyte colony stimulating factor (GM-CSF (NV1034)) or interluken-12 (IL-12 (NV1042)) cytokine genes. These were compared to saline and control virus (NV1023) in vitro and in vivo. HSV-1 mutants were assessed for cytotoxicity, replication and cytokine expression in CT-26 cells. A syngeneic micrometastatic liver model was then established in naive and immune cell-depleted animals to assess the antitumor efficacy of these viruses. In vitro cytotoxicity and viral replication were similar for each virus, resulting in greater than 80 and 98% cytotoxicity at multiplicity of infection of 1 and 10, respectively. Peak viral titers were 25- to 50-fold higher than initial titer and were not significantly different between viruses. In vivo, all three viruses reduced metastases relative to control, but cytokine-secreting viruses did so with greater efficacy compared to NV1023. This effect was abrogated by T-cell depletion, but not NK-cell depletion. Single-agent therapy with oncolytic viral agents containing GM-CSF or IL-12 is effective in a murine model of liver metastases and likely involves direct viral oncolysis and actions of specific immune effector cells.

KW - Cytokine gene therapy

KW - HSV

KW - Liver cancer

KW - Metastases

KW - Murine model

KW - Oncolytic viral therapy

UR - http://www.scopus.com/inward/record.url?scp=34249086265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249086265&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7701053

DO - 10.1038/sj.cgt.7701053

M3 - Article

C2 - 17431402

AN - SCOPUS:34249086265

VL - 14

SP - 590

EP - 597

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 6

ER -